RE:RE:RE:RE:RE:ONCY announces Pelareorep ≥50% ORR & mPFS Improvements Important in the last reported Bracelet-1 results is that pelareorep as a monotherapy in combination with paclitaxel (cohort 2) resulted in a near tripling of confirmed overall response rate (ORR), a surrogate endpoint (biomarker), that could prompt the filing of an accelerated approval.